Amphastar Pharmaceuticals Gross Margin 2012-2026 | AMPH
Current and historical gross margin for Amphastar Pharmaceuticals (AMPH) over the last 10 years. The current gross profit margin for Amphastar Pharmaceuticals as of March 31, 2026 is %.
| Amphastar Pharmaceuticals Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2026-03-31 | $0.72B | $0.34B | 47.36% |
| 2025-12-31 | $0.72B | $0.36B | 49.44% |
| 2025-09-30 | $0.72B | $0.36B | 49.31% |
| 2025-06-30 | $0.72B | $0.36B | 49.79% |
| 2025-03-31 | $0.73B | $0.37B | 50.48% |
| 2024-12-31 | $0.73B | $0.37B | 51.09% |
| 2024-09-30 | $0.72B | $0.38B | 52.97% |
| 2024-06-30 | $0.71B | $0.39B | 54.56% |
| 2024-03-31 | $0.68B | $0.37B | 54.21% |
| 2023-12-31 | $0.65B | $0.35B | 54.42% |
| 2023-09-30 | $0.60B | $0.33B | 54.15% |
| 2023-06-30 | $0.54B | $0.28B | 51.20% |
| 2023-03-31 | $0.52B | $0.27B | 51.54% |
| 2022-12-31 | $0.50B | $0.25B | 50.00% |
| 2022-09-30 | $0.48B | $0.23B | 48.35% |
| 2022-06-30 | $0.48B | $0.23B | 47.48% |
| 2022-03-31 | $0.46B | $0.21B | 46.15% |
| 2021-12-31 | $0.44B | $0.20B | 45.43% |
| 2021-09-30 | $0.41B | $0.18B | 43.58% |
| 2021-06-30 | $0.38B | $0.17B | 43.23% |
| 2021-03-31 | $0.37B | $0.15B | 41.30% |
| 2020-12-31 | $0.35B | $0.14B | 41.14% |
| 2020-09-30 | $0.34B | $0.14B | 41.54% |
| 2020-06-30 | $0.33B | $0.14B | 41.32% |
| 2020-03-31 | $0.33B | $0.14B | 41.90% |
| 2019-12-31 | $0.32B | $0.13B | 40.68% |
| 2019-09-30 | $0.33B | $0.13B | 40.43% |
| 2019-06-30 | $0.33B | $0.13B | 39.08% |
| 2019-03-31 | $0.32B | $0.12B | 38.17% |
| 2018-12-31 | $0.30B | $0.11B | 36.27% |
| 2018-09-30 | $0.27B | $0.09B | 34.72% |
| 2018-06-30 | $0.25B | $0.08B | 34.01% |
| 2018-03-31 | $0.24B | $0.09B | 35.27% |
| 2017-12-31 | $0.24B | $0.09B | 37.92% |
| 2017-09-30 | $0.24B | $0.09B | 37.30% |
| 2017-06-30 | $0.25B | $0.10B | 39.20% |
| 2017-03-31 | $0.25B | $0.10B | 40.71% |
| 2016-12-31 | $0.26B | $0.11B | 41.18% |
| 2016-09-30 | $0.27B | $0.12B | 44.03% |
| 2016-06-30 | $0.27B | $0.11B | 40.30% |
| 2016-03-31 | $0.25B | $0.09B | 35.04% |
| 2015-12-31 | $0.25B | $0.08B | 30.56% |
| 2015-09-30 | $0.23B | $0.06B | 24.24% |
| 2015-06-30 | $0.23B | $0.05B | 22.03% |
| 2015-03-31 | $0.22B | $0.05B | 23.42% |
| 2014-12-31 | $0.21B | $0.05B | 24.64% |
| 2014-09-30 | $0.21B | $0.06B | 28.57% |
| 2014-06-30 | $0.21B | $0.07B | 32.54% |
| 2014-03-31 | $0.22B | $0.08B | 35.87% |
| 2013-12-31 | $0.23B | $0.09B | 37.83% |
| 2013-09-30 | $0.23B | $0.12B | 52.42% |
| 2013-06-30 | $0.23B | $0.16B | 69.33% |
| 2013-03-31 | $0.21B | $0.18B | 84.36% |
| 2012-12-31 | $0.20B | $0.20B | 100.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.924B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |